Management of Asymptomatic Hyperuricemia

Introduction to Asymptomatic Hyperuricemia

The American College of Rheumatology conditionally recommends against initiating urate-lowering therapy for asymptomatic hyperuricemia, based on high-certainty evidence showing limited benefit relative to potential risks 5
Asymptomatic hyperuricemia is defined as serum urate >6.8 mg/dL with no prior gout flares or subcutaneous tophi 5

Multiple international guidelines from rheumatology societies agree that pharmacological treatment of asymptomatic hyperuricemia is not recommended 1, 6
The most recent KDIGO 2024 guidelines suggest not using agents to lower serum uric acid in people with CKD and asymptomatic hyperuricemia to delay CKD progression (Grade 2D recommendation) 2, 3, 4
Among patients with asymptomatic hyperuricemia with serum urate >9 mg/dL, only 20% developed gout within 5 years 5
The number needed to treat is high: 24 patients would need urate-lowering therapy for 3 years to prevent a single gout flare 5

For all patients with asymptomatic hyperuricemia, lifestyle modifications should be advised 1, 8
Reduce excess body weight if obese 1, 6
Perform regular exercise 1
Smoking cessation 1
Avoid excess alcohol consumption, especially beer 1, 6
Limit sugar-sweetened drinks and high-fructose corn syrup intake 2, 3, 4
Reduce consumption of purine-rich meats 2, 3, 4

After the first gout flare with serum urate >9 mg/dL, urate-lowering therapy should be initiated 7, 5
With subcutaneous tophi, radiographic damage, or frequent gout flares (≥2/year), urate-lowering therapy is strongly recommended 5
Start allopurinol at low dose (≤100 mg daily, lower in CKD stage ≥3) with subsequent dose titration to achieve target serum urate <6 mg/dL 5